Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE: Chidamide + Exemestane in HR+ Advanced Breast Cancer
NCT02482753Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tucidinostat in breast cancer (3 arms), sponsored by Akeso, Inc. Primary endpoints: Progression-Free Survival at 3 years, Pharmacokinetic profiles of Chidamide and 2 more. Started Jul 2015; status: completed.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02482753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482753.